Literature DB >> 1247497

Factor VIII and factor-VIII-related antigen in multiple myelomatosis and related conditions.

E D Gomperts, G Shulman, S R Lynch.   

Abstract

Factor VIII and factor-VIII-related antigen (FVIIIRA) were estimated in 19 patients with paraproteinaemia. The FVIIIRA levels were above the normal range in 12 cases with II of these showing an abnormal FVIII/FVIIIRA ratio. The patients could be subdivied into three groups according to their FVIIIRA levels: normal levels, levels greater than normal but less than 200%, greater than 200%. This subdivision correlated with the degree of bone involvement as assessed by radiological skeletal survey.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1247497     DOI: 10.1111/j.1365-2141.1976.tb00928.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Maeve P Crowley; Maeve P Crowely; Shane Quinn; Eoin Coleman; Joseph A Eustace; Oonagh M Gilligan; Susan I O'Shea; Susan I O Shea
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  Plasma Levels of Vascular Endothelial Growth Factor and Selected Hemostatic Parameters in Association With Treatment Response in Multiple Myeloma.

Authors:  Juraj Sokol; Matej Hrncar; Frantisek Nehaj; Jan Stasko
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 3.  Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.

Authors:  Claire Comerford; Siobhan Glavey; Jamie M O'Sullivan; John Quinn
Journal:  Cancer Drug Resist       Date:  2022-03-07

Review 4.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.